{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:13:55Z","timestamp":1794507235269,"version":"4.9.1"},"reference-count":141,"publisher":"Oxford University Press (OUP)","issue":"26","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite significant advances in lipid-lowering therapeutics, residual lipid risk persists in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), even after optimizing low-density lipoprotein (LDL) cholesterol. Emerging evidence highlights the role of non-LDL cholesterol fractions, such as remnant cholesterol, lipoprotein(a) [Lp(a)], apolipoprotein B (apoB), and non-high-density lipoprotein (HDL) cholesterol, as key contributors to residual ASCVD risk. Remnant cholesterol, Lp(a), and LDL cholesterol represent three independent lipoprotein species causing ASCVD, while apolipoprotein B (apoB) and non-HDL cholesterol integrate the other three variables. Thus, clinically interpreting elevated apoB and non-HDL cholesterol is potentially complicated since remnants, Lp(a), and LDL cause ASCVD by different mechanisms and by varying proportions in different patients. Indeed, recent research into the pathophysiology of lipid-driven atherogenesis and development of ASCVD has revealed novel mechanisms that in turn suggest new therapeutic strategies targeting non-LDL lipid components. Elevated remnant cholesterol jointly with elevated LDL cholesterol contributes to arterial wall cholesterol deposition, plaque development, and ASCVD endpoints. Furthermore, the additional triglyceride content in remnant particles may theoretically promote intimal inflammation and possibly plaque rupture and erosion, independently contributing to atherogenesis and ASCVD. The lipid component and pro-inflammatory properties of Lp(a) could similarly contribute directly to atherosclerotic plaque development and ASCVD. In addition, the homology with plasminogen of the defining apolipoprotein(a) moiety of Lp(a) has long been speculated to confer anti-fibrinolytic and pro-thrombotic properties that could produce more severe ASCVD outcomes independent of atherogenesis. This review explores the evolving understanding of residual lipid risk in ASCVD, practical guidance for clinicians today, recent advances in therapeutic interventions, and their implications for clinical practice, aiming to optimize lipid management beyond LDL cholesterol reduction today and in the future.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag087","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:11:21Z","timestamp":1769515881000},"page":"3347-3365","source":"Crossref","is-referenced-by-count":29,"title":["Residual lipid risk in atherosclerotic cardiovascular disease"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G","family":"Nordestgaard","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte , Borgmester Ib Juuls vej 73, Herlev DK-2730 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Blegdamsvej 3B, Copenhagen N DK-2200 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Hegele","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Western Ontario , London, Ontario ,","place":["Canada"]},{"name":"Robarts Research Institute, University of Western Ontario , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2026070619572627700_ehag087-B1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B2","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B3","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B4","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B5","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B6","doi-asserted-by":"publisher","first-page":"117312","DOI":"10.1016\/j.atherosclerosis.2023.117312","article-title":"Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook","volume":"383","author":"Raja","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026070619572627700_ehag087-B7","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1093\/eurheartj\/ehaf204","article-title":"Apob and Lp(a): core measures to assess cardiovascular risk","volume":"46","author":"Sniderman","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B8","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/s0140-6736(24)01308-4","article-title":"Langsted A. Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"2026070619572627700_ehag087-B10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2026070619572627700_ehag087-B11","doi-asserted-by":"publisher","first-page":"1264319","DOI":"10.3389\/fcvm.2023.1264319","article-title":"High residual cardiovascular risk after lipid-lowering: prime time for predictive, preventive, personalized, participatory, and psycho-cognitive medicine","volume":"10","author":"Reijnders","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026070619572627700_ehag087-B12","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeae057","article-title":"It is time to address the contribution of cholesterol in all apoB-containing lipoproteins to atherosclerotic cardiovascular disease","volume":"4","author":"Toth","year":"2024","journal-title":"Eur Heart J Open"},{"key":"2026070619572627700_ehag087-B13","doi-asserted-by":"publisher","first-page":"119139","DOI":"10.1016\/j.atherosclerosis.2025.119139","article-title":"Discordance analyses comparing LDL cholesterol, non-HDL cholesterol, and apolipoprotein B for cardiovascular risk estimation","volume":"403","author":"Johannesen","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026070619572627700_ehag087-B14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.12997\/jla.2025.14.3.247","article-title":"Triglycerides, triglyceride-rich lipoproteins, and remnant cholesterol in atherosclerotic cardiovascular disease","volume":"14","author":"Jo","year":"2025","journal-title":"J Lipid Atheroscler"},{"key":"2026070619572627700_ehag087-B15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/jcdd12070256","article-title":"The role of non-HDL cholesterol and apolipoprotein B in cardiovascular disease: a comprehensive review","volume":"12","author":"Katsi","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"key":"2026070619572627700_ehag087-B16","doi-asserted-by":"publisher","first-page":"25985","DOI":"10.31083\/rcm25985","article-title":"Remnant cholesterol and residual risk of atherosclerotic cardiovascular disease","volume":"26","author":"Li","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"2026070619572627700_ehag087-B17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacl.2025.05.024","article-title":"Apob, LDL-C, and non-HDL-C as markers of cardiovascular risk","volume":"19","author":"Sehayek","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026070619572627700_ehag087-B18","doi-asserted-by":"publisher","first-page":"e025858","DOI":"10.1161\/jaha.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026070619572627700_ehag087-B19","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1093\/eurheartj\/ehaf214","article-title":"Great debate: plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease","volume":"46","author":"Bor\u00e9n","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B20","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B21","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"2026070619572627700_ehag087-B23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"2026070619572627700_ehag087-B24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/mol.0000000000000921","article-title":"Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events","volume":"35","author":"Raggi","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"2026070619572627700_ehag087-B25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/clinchem\/hvae217","article-title":"Remnant cholesterol: quantification, concentrations by sex and age, and risk of ischemic heart disease","volume":"71","author":"Balling","year":"2025","journal-title":"Clin Chem"},{"key":"2026070619572627700_ehag087-B26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/0300985811417248","article-title":"Pancreatitis in hyperlipemic mink (Mustela vison)","volume":"49","author":"Nordstoga","year":"2012","journal-title":"Vet Pathol"},{"key":"2026070619572627700_ehag087-B27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"2026070619572627700_ehag087-B28","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"2026070619572627700_ehag087-B29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1373\/clinchem.2018.294926","article-title":"Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population","volume":"65","author":"Hansen","year":"2019","journal-title":"Clin Chem"},{"key":"2026070619572627700_ehag087-B30","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1161\/atvbaha.111.226100","article-title":"Triglycerides and heart disease: still a hypothesis?","volume":"31","author":"Goldberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572627700_ehag087-B31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1126\/science.2530631","article-title":"The mysteries of lipoprotein(a)","volume":"246","author":"Utermann","year":"1989","journal-title":"Science"},{"key":"2026070619572627700_ehag087-B32","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"2026070619572627700_ehag087-B33","first-page":"2753","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Utermann","year":"2001","edition":"8th ed"},{"key":"2026070619572627700_ehag087-B34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"2026070619572627700_ehag087-B35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"2026070619572627700_ehag087-B36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/scientificamerican0692-54","article-title":"Lipoprotein(a) in heart disease","volume":"266","author":"Lawn","year":"1992","journal-title":"Sci Am"},{"key":"2026070619572627700_ehag087-B37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/330113a0","article-title":"Plasma lipoproteins: teaching old dogmas new tricks","volume":"330","author":"Brown","year":"1987","journal-title":"Nature"},{"key":"2026070619572627700_ehag087-B38","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"2026070619572627700_ehag087-B39","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/01.RES.78.4.615","article-title":"Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo","volume":"78","author":"Nielsen","year":"1996","journal-title":"Circ Res"},{"key":"2026070619572627700_ehag087-B40","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B41","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1161\/circulationaha.120.045826","article-title":"Lipoprotein(a) in Alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"key":"2026070619572627700_ehag087-B42","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B43","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jacc.2024.07.034","article-title":"Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk assessment using non-HDL cholesterol","volume":"84","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ng.3561","article-title":"Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease","volume":"48","author":"Helgadottir","year":"2016","journal-title":"Nat Genet"},{"key":"2026070619572627700_ehag087-B46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026070619572627700_ehag087-B47","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B48","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1056\/nejm197606172942509","article-title":"Familial hypercholesterolemia: a genetic defect in the low-density lipoprotein receptor","volume":"294","author":"Brown","year":"1976","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1373\/clinchem.2017.279463","article-title":"Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the Copenhagen general population study","volume":"64","author":"Varbo","year":"2018","journal-title":"Clin Chem"},{"key":"2026070619572627700_ehag087-B50","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin Chem"},{"key":"2026070619572627700_ehag087-B51","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/circulationaha.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"key":"2026070619572627700_ehag087-B52","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1161\/atvbaha.124.321387","article-title":"Impaired renal function with higher remnant cholesterol related to risk of atherosclerotic cardiovascular disease: a cohort study","volume":"44","author":"El\u00edas-L\u00f3pez","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572627700_ehag087-B53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"2026070619572627700_ehag087-B54","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"2026070619572627700_ehag087-B55","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B56","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B57","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration. Type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026070619572627700_ehag087-B58","doi-asserted-by":"publisher","first-page":"845","DOI":"10.26599\/1671-5411.2023.12.001","article-title":"Discordance analysis for apolipoprotein and lipid measures for predicting myocardial infarction in statin-treated patients with coronary artery disease: a cohort study","volume":"20","author":"Li","year":"2023","journal-title":"J Geriatr Cardiol"},{"key":"2026070619572627700_ehag087-B59","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in End-points through aggressive lipid lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026070619572627700_ehag087-B60","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B61","doi-asserted-by":"publisher","first-page":"120411","DOI":"10.1016\/j.atherosclerosis.2025.120411","article-title":"Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease","volume":"408","author":"Schuitema","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026070619572627700_ehag087-B62","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B63","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","article-title":"Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B64","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1093\/eurheartj\/ehaf274","article-title":"Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a)","volume":"46","author":"Wulff","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B65","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/cir.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2026070619572627700_ehag087-B66","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026070619572627700_ehag087-B67","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1016\/j.jacl.2024.01.006","article-title":"Lipid association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: consensus statement IV","volume":"18","author":"Puri","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026070619572627700_ehag087-B68","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/j.jacc.2025.02.024","article-title":"Lipoprotein(a) cardiovascular risk explained by LDL cholesterol, non-HDL cholesterol, ApoB, or hsCRP is minimal","volume":"85","author":"Thomas","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B69","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026070619572627700_ehag087-B70","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/clinchem\/hvad094","article-title":"Hypertriglyceridemia-associated pancreatitis: new concepts and potential mechanisms","volume":"69","author":"Hansen","year":"2023","journal-title":"Clin Chem"},{"key":"2026070619572627700_ehag087-B71","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"2026070619572627700_ehag087-B72","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"2026070619572627700_ehag087-B73","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026070619572627700_ehag087-B74","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jacc.2017.08.006","article-title":"A test in context: lipid profile, fasting versus nonfasting","volume":"70","author":"Nordestgaard","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B75","doi-asserted-by":"publisher","first-page":"119218","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The Brussels international declaration on lipoprotein(a) testing and management","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026070619572627700_ehag087-B76","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen General Population Study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026070619572627700_ehag087-B77","doi-asserted-by":"publisher","first-page":"oead035","DOI":"10.1093\/ehjopen\/oead035","article-title":"Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up","volume":"3","author":"Ziogos","year":"2023","journal-title":"Eur Heart J Open"},{"key":"2026070619572627700_ehag087-B78","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/0735-1097(93)90213-k","article-title":"Myocardial injury: the acute phase response and lipoprotein metabolism","volume":"22","author":"Rosenson","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B79","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacl.2021.09.046","article-title":"Lipid measurements in the management of cardiovascular diseases: practical recommendations a scientific statement from the national lipid association writing group","volume":"15","author":"Wilson","year":"2021","journal-title":"J Clin Lipidol"},{"key":"2026070619572627700_ehag087-B80","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.jacc.2024.03.423","article-title":"Excess apolipoprotein B and cardiovascular risk in women and men","volume":"83","author":"Johannesen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572627700_ehag087-B81","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/circulationaha.113.005873","article-title":"Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events","volume":"129","author":"Mora","year":"2014","journal-title":"Circulation"},{"key":"2026070619572627700_ehag087-B82","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B83","doi-asserted-by":"publisher","first-page":"e030405","DOI":"10.1161\/jaha.123.030405","article-title":"Standardization of apolipoprotein B, LDL-cholesterol, and non-HDL-cholesterol","volume":"12","author":"Contois","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026070619572627700_ehag087-B84","doi-asserted-by":"publisher","first-page":"119241","DOI":"10.1016\/j.atherosclerosis.2025.119241","article-title":"Association of low-grade inflammation and elevated remnant cholesterol with risk of ASCVD and mortality in impaired renal function","volume":"406","author":"El\u00edas-L\u00f3pez","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026070619572627700_ehag087-B85","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1007\/s00125-023-06016-0","article-title":"Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study","volume":"66","author":"Wadstr\u00f6m","year":"2023","journal-title":"Diabetologia"},{"key":"2026070619572627700_ehag087-B86","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ihj.2017.02.020","article-title":"Recent trends in epidemiology of dyslipidemias in India","volume":"69","author":"Gupta","year":"2017","journal-title":"Indian Heart J"},{"key":"2026070619572627700_ehag087-B87","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.ihj.2023.11.271","article-title":"CSI clinical practice guidelines for dyslipidemia management: executive summary","volume":"76","author":"Sawhney","year":"2024","journal-title":"Indian Heart J"},{"key":"2026070619572627700_ehag087-B88","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12889-020-8378-5","article-title":"Metabolic syndrome in indigenous communities in Mexico: a descriptive and cross-sectional study","volume":"20","author":"Mendoza-Caamal","year":"2020","journal-title":"BMC Public Health"},{"key":"2026070619572627700_ehag087-B89","first-page":"1263","article-title":"Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"2016","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"2026070619572627700_ehag087-B90","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2020.01.020","article-title":"Methodological issues regarding: \u201cA third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals\u201d","volume":"302","author":"Remaley","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026070619572627700_ehag087-B91","first-page":"2835","volume-title":"The Metabolic & Molecular Bases of Inherited Disease","author":"Mahley","year":"2001","edition":"8 edn"},{"key":"2026070619572627700_ehag087-B92","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s11883-014-0440-2","article-title":"Hyperlipoproteinemia type 3: the forgotten phenotype","volume":"16","author":"Hopkins","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"2026070619572627700_ehag087-B93","doi-asserted-by":"publisher","first-page":"e3528","DOI":"10.1210\/clinem\/dgae804","article-title":"Dysbetalipoproteinemia: focus on a neglected lipid disorder","volume":"110","author":"Berberich","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070619572627700_ehag087-B94","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B95","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/atvbaha.112.300154","article-title":"Mechanisms of coronary thrombosis in cigarette smoke exposure","volume":"33","author":"Barua","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572627700_ehag087-B96","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/01.hjr.0000087913.96265.e2","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)","volume":"10","author":"De Backer","year":"2003","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026070619572627700_ehag087-B97","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B98","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026070619572627700_ehag087-B99","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/01.ATV.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","author":"Grundy","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572627700_ehag087-B100","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"2026070619572627700_ehag087-B101","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B102","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B103","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B104","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B105","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B106","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B107","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","author":"Marston","year":"8, 2025","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B109","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B110","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/s0140-6736(25)00825-6","article-title":"Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies","volume":"405","author":"Cummings","year":"2025","journal-title":"Lancet"},{"key":"2026070619572627700_ehag087-B111","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/s41591-025-03830-4","article-title":"Targeting the angiopoietin-like protein 3\/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial","volume":"31","author":"Gaudet","year":"2025","journal-title":"Nat Med"},{"key":"2026070619572627700_ehag087-B112","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B113","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1161\/atvbaha.120.315757","article-title":"LEGACY: phase 2a trial to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of the anti-EL (endothelial lipase) antibody MEDI5884 in patients with stable coronary artery disease","volume":"41","author":"Ruff","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572627700_ehag087-B114","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"key":"2026070619572627700_ehag087-B115","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B116","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/s2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070619572627700_ehag087-B117","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B118","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/mol.0000000000000960","article-title":"Fibroblast growth factor 21: update on genetics and molecular biology","volume":"36","author":"Barros","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"2026070619572627700_ehag087-B119","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Lau F","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026070619572627700_ehag087-B120","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on Major cardiovascular events in patients with CVD and elevated lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"2026070619572627700_ehag087-B122","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B123","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"2026070619572627700_ehag087-B124","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"2026070619572627700_ehag087-B125","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"2026070619572627700_ehag087-B126","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial","volume":"331","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"2026070619572627700_ehag087-B127","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1463-1326.2011.01383.x","article-title":"Lipid-altering efficacy and safety profile of combination therapy with ezetimibe\/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials","volume":"13","author":"Leiter","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2026070619572627700_ehag087-B128","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/atvbaha.120.315446","article-title":"Effects of evolocumab on the postprandial kinetics of apo (apolipoprotein) B100- and B48-containing lipoproteins in subjects with type 2 diabetes","volume":"41","author":"Taskinen","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572627700_ehag087-B129","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf337","article-title":"Remnant cholesterol lowering in cardiovascular disease risk reduction in statin, ezetimibe, and PCSK9 inhibitor trials: meta-regression analyses","author":"Nordestgaard","year":"12, 2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026070619572627700_ehag087-B130","doi-asserted-by":"publisher","first-page":"J21","DOI":"10.1093\/eurheartj\/suaa116","article-title":"Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap","volume":"22","author":"Parhofer","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"2026070619572627700_ehag087-B131","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/fjc.0000000000000963","article-title":"Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis","volume":"77","author":"Farmakis","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026070619572627700_ehag087-B132","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070619572627700_ehag087-B133","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","article-title":"Familial chylomicronemia syndrome: an expert clinical review from the national lipid association","volume":"19","author":"Javed","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026070619572627700_ehag087-B134","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/s2213-8587(25)00028-2","article-title":"Futility of plasmapheresis, insulin in normoglycaemic individuals, or heparin in the treatment of hypertriglyceridaemia-induced acute pancreatitis","volume":"13","author":"Syed-Abdul","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070619572627700_ehag087-B135","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/mol.0000000000000920","article-title":"ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?","volume":"35","author":"Chan","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"2026070619572627700_ehag087-B136","first-page":"2789","volume-title":"The Metabolic & Molecular Bases of Inherited Disease","author":"Brunzell","year":"2001","edition":"8 edn"},{"key":"2026070619572627700_ehag087-B137","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070619572627700_ehag087-B138","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/mol.0000000000000898","article-title":"Angiopoietin-like 3 inhibition and the liver: less is more?","volume":"34","author":"Oostveen","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"2026070619572627700_ehag087-B139","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/mol.0000000000000800","article-title":"ANGPTL4: a new mode in the regulation of intravascular lipolysis","volume":"33","author":"Ploug","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"2026070619572627700_ehag087-B140","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/mol.0000000000000910","article-title":"Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism","volume":"35","author":"Wen","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"2026070619572627700_ehag087-B141","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/s0140-6736(24)02089-0","article-title":"Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)","volume":"404","author":"Strandberg","year":"2024","journal-title":"Lancet"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/26\/3347\/66961405\/ehag087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/26\/3347\/66961405\/ehag087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:57:38Z","timestamp":1783382258000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/26\/3347\/8488862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":141,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag087","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,7]]},"published":{"date-parts":[[2026,2,17]]}}}